Lenalidomide Maintenance May Prolong Progression-free Survival in DLBCL

Share this content:
The phase 3 REMARC study enrolled 650 treatment-naive patients with DLBCL or other aggressive B cell lymphomas.
The phase 3 REMARC study enrolled 650 treatment-naive patients with DLBCL or other aggressive B cell lymphomas.

Patients with diffuse large B cell lymphoma (DLBCL) who receive maintenance therapy with lenalidomide for 2 years after a complete (CR) or partial response (PR) with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) may have prolonged progression-free survival (PFS), according to a study published in the Journal of Clinical Oncology.1

The phase 3 REMARC study (ClinicalTrials.gov Identifier: NCT01122472) enrolled 650 treatment-naive patients with DLBCL or other aggressive B cell lymphomas. Patients who had a CR or PR with R-CHOP were randomly assigned to receive lenalidomide 25mg/day or placebo for 24 months. 

When primary analysis was performed at a median follow-up of 39 months, patients who received lenalidomide maintenance did not reach a median PFS vs 58.9 months for placebo (hazard ratio [HR], 0.708; 95% CI, 0.537-0.933; P = .01).

The 2-year PFS in the lenalidomide group improved to 80% (95% CI, 75%-84%) from 75% (95% CI, 70%-80%).

The 2-year overall survival (OS) in the lenalidomide arm was estimated at 87% (95% CI, 82%-90%) vs 89% (95% CI, 85%-92%) in the placebo arm (log-rank test P = .2640; HR, 1.218; 95% CI, 0.861-1.721).

Median overall survival (OS) was similar in both study arms at a median follow-up of 52 months (HR 1.218; 95% CI, 0.861-1.721; P = .26). 

RELATED: Mantle Cell Lymphoma: Evaluating the Treatment Landscape

Almost 90% of patients reported at least 1 treatment related adverse event (AE). The most frequently reported grade 3 to 4 AEs in lenalidomide vs placebo were neutropenia (56% vs 22%, respectively) and cutaneous reactions (5% v 1%, respectively).

Reference

  1. Thieblemont C, Tilly H, Gomes Da Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 20 April 2017. doi: 10.1200/JCO.2017.72.6984 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters